Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)

A Phase III Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of V260 in Healthy Infants in Japan

The purpose of the study is to evaluate whether V260 is effective and well tolerated in Japanese healthy infants.

Inclusion Criteria:

• Healthy Japanese Infants, 6 Weeks Through 12 Weeks Of Age

Exclusion Criteria:

• History Of Known Prior Rotavirus Gastroenteritis
• Subjects Who Are Concurrently Participating In Or Are Anticipated To Participate In Other Studies Of Investigational Products At Any Time During The Study Period